TABLE 6.
Meta-Analyses of Citicoline Studies Intent-to-Treat Set: GEE Estimated Probabilities of Global Recovery after 12 Weeks of Follow-Up163
| Global Recovery at Week 12
|
|||||
|---|---|---|---|---|---|
| Citicoline % | Placebo % | OR | 95% CI | p | |
| Citicoline vs. placebo (4 trials, 1372 patients) | 25.2 | 20.2 | 1.33 | 1.10–1.62 | 0.0034 |
| Doses | |||||
| Citicoline 500 mg vs. placebo | |||||
| Study 001a6 | 27.7 | 11.4 | 2.98 | 1.25–7.02 | 0.0129 |
| Study 0077 | 24.2 | 16.6 | 1.61 | 0.93–2.78 | 0.0890 |
| Study 0108 | 17.1 | 24.0 | 0.65 | 0.28–1.48 | 0.3078 |
| Overall | 20.8 | 15.7 | 1.42 | 0.96–2.093 | 0.0782 |
| Citicoline 1000 mg vs. placebo | |||||
| Study 001a6 | 9.1 | 10.7 | 0.84 | 0.35–2.15 | 0.7096 |
| Citicoline 2000 mg vs. placebo | |||||
| Study 001a6 | 25.19 | 9.8 | 3.098 | 1.18–8.12 | 0.0214 |
| Study 0189 | 28.47 | 23.25 | 1.314 | 1.0–1.65 | 0.0183 |
| Overall | 27.9 | 21.9 | 1.38 | 1.10–1.72 | 0.0043 |
OR = odds ratio. From Daralos et al. Oral citicoline in acute stroke: an individual patient data pooling analysis of clinical trials. Stroke 33:2850–2857. Copyright © 2002, Lippincott Williams and Wilkins. All rights reserved.